NRx Pharmaceuticals (NRXP) Projected to Post Quarterly Earnings on Wednesday

NRx Pharmaceuticals (NASDAQ:NRXP) is projected to announce its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Thursday, May 15th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06. The firm had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.14 million. On average, analysts expect NRx Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NRx Pharmaceuticals Stock Performance

NRx Pharmaceuticals stock opened at $2.52 on Monday. The firm has a market cap of $43.57 million, a price-to-earnings ratio of -1.25 and a beta of 1.59. NRx Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $6.01. The firm’s 50 day moving average price is $3.10 and its two-hundred day moving average price is $2.59.

Institutional Trading of NRx Pharmaceuticals

A hedge fund recently raised its stake in NRx Pharmaceuticals stock. Geode Capital Management LLC increased its stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) by 27.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 172,255 shares of the company’s stock after purchasing an additional 37,598 shares during the quarter. Geode Capital Management LLC owned about 1.00% of NRx Pharmaceuticals worth $562,000 at the end of the most recent quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NRXP. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Ascendiant Capital Markets lifted their price objective on shares of NRx Pharmaceuticals from $45.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. Finally, D. Boral Capital reiterated a “buy” rating and set a $31.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday, August 4th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $28.50.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.